Research programme: cancer therapeutics - Endo/Jubilant

Drug Profile

Research programme: cancer therapeutics - Endo/Jubilant

Alternative Names: CYP17A1 inhibitor - Endo/Jubilant; EN-3356

Latest Information Update: 01 Nov 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Endo Pharmaceuticals; Jubilant Biosys
  • Class Small molecules
  • Mechanism of Action Steroid 17-alpha-hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Prostate cancer

Most Recent Events

  • 22 Oct 2013 Pharmacodynamics data from preclinical studies of EN 3356 presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2013)
  • 07 Aug 2013 Preclinical trials in Prostate cancer in India (PO)
  • 07 Aug 2013 Preclinical trials in Prostate cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top